Jun 04, 2020
New Long-term Data from RINVOQ(TM) (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
Apr 23, 2020
Study Underway to Examine the Planned Use of Voraxaze® with Methotrexate in CNS Lymphoma
Dec 18, 2019
AbbVie Receives European Commission Approval of RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Dec 02, 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Aug 16, 2019
AbbVie Receives FDA Approval of RINVOQ(TM) (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
Jul 11, 2019
NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®
Feb 14, 2019
A Retrospective Study of Medicare Claim Data Shows Patients Treated with Voraxaze® had Shorter Hospitalizations and Lower Mortality
Oct 23, 2018
AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data
Jun 05, 2018
Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis
Dec 20, 2017
AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
Nov 16, 2017
New Consensus Guidelines Provide Specific Recommendations for Use of Voraxaze® in Patients with Delayed Methotrexate Clearance
Jul 31, 2017
Xatmep - The First and Only Ready-To-Use Methotrexate Oral Solution is Now Available